Search

Displaying results 2431 - 2440 of 10000 in total
  1. Drug

    Lumateperone

    go.drugbank.com/drugs/DB06077
    ApprovedInvestigational

    [A189093] It has a unique receptor binding profile and differs from other antipsychotics in that it modulates glutamate, serotonin and dopamine, which are all neurotransmitters that contribute to the pathophysiology … [A189093] Further, not only is the new antipsychotic selective for dopamine (D2) receptors in the mesolimbic and mesocortical brain regions, but it also has minimal off-target activity.

  2. Drug

    Palopegteriparatide

    go.drugbank.com/drugs/DB18676
    ApprovedInvestigational

    [A264199] Upon administration, PTH is cleaved from palopegteriparatide in a controlled manner to achieve a continuous systemic exposure of active PTH. … [L51134] PTH(1-34) contains the N-terminal part of the endogenous PTH molecule.

    Synonyms: Poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbonyl]-2-methylalanyl-L-seryl-L-valyl-L-seryl-L-α-glutamyl-L-isole, Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34
  3. Drug

    Coenzyme M

    go.drugbank.com/drugs/DB09110
    ApprovedInvestigational

    Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.[A18572]

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Fremanezumab

    go.drugbank.com/drugs/DB14041
    ApprovedInvestigational

    [L11779] Along with other recently approved anti-CGRP therapies such as [galcanezumab], [erenumab], and the oral CGRP antagonist [ubrogepant], fremanezumab represents an important step forward in the treatment … [L11749] It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018.

    Products: AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5ML, Ajovy Filled Pen
  5. Drug

    Seladelpar

    go.drugbank.com/drugs/DB12390
    ApprovedInvestigational

    [L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism … Seladelpar is a peroxisome proliferator-activated receptor (PPAR)-delta (δ) agonist. Seladelpar is a single enantiomer of the R-configuration.

  6. Drug

    Acetarsol

    go.drugbank.com/drugs/DB13268
    ApprovedWithdrawn

    Acetarsol, with the molecular formula N-acetyl-4-hydroxy-m-arsanilic acid, is a pentavalent arsenical compound with antiprotozoal and antihelmintic properties. … [L2622] It was first discovered in 1921 by Ernest Fourneau at the Pasteur Institute. It was developed by Neolab Inc, and approved by Health Canada as an antifungal on December 31, 1964.

  7. Drug

    Sulfur hexafluoride

    go.drugbank.com/drugs/DB11104
    ApprovedInvestigational

    in adult patients with suboptimal echocardiograms •in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients … Sulfur hexafluoride is an ultrasound contrast agent indicated for use •in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border

  8. Drug

    Odevixibat

    go.drugbank.com/drugs/DB16261
    ApprovedInvestigational

    [L34803] Previous therapies for PFIC included a bile acid sequestrant such as [ursodeoxycholic acid]. … Odevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familial intrahepatic cholestasis (PFIC

  9. Drug

    Belimumab

    go.drugbank.com/drugs/DB08879
    ApprovedInvestigational

    It is produced by recombinant DNA technology in a murine cell (NS0) expression system. … [L42630] Belimumab was first approved by the FDA on March 9, 2011,[A251495] making it the newest drug to be approved for the treatment of SLE in more than 50 years.

  10. Drug

    Xanomeline

    go.drugbank.com/drugs/DB15357
    ApprovedInvestigational

    [L51713] It is approved as part of a combination product alongside [trospium], a muscarinic antagonist that acts primarily on peripheral muscarinic receptors in order to mitigate the risk and severity … [A264509] Advances in pre-clinical research and findings in clinical trials have led to a resurgence of interest in the cognition-enhancing potential of muscarinic agonists in schizophrenia, as it was